Home › Research › Treatments
Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes
Dror Shir, Nick Corriveau‐Lecavalier, David Thomas Jones, Vijay K. Ramanan, Christian Lachner, David S. Knopman, Ronald Carl Petersen, Keith A. Josephs et al.. Neurology, 2026-08-05
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
= 0.036), with lower scores in PCA and lvPPA (median 21 and 21, respectively) compared with CBS-AD (median 27). Depending on the eligibility framework applied, 70%-85% of patients would not meet treatment criteria. Bedside cognitive thresholds were the primary drivers of ineligibility (50%-67% of exclusions), despite most patients having early symptomatic disease (global CDR 0.5-1; 82%). Imaging-based exclusions (22%-27%) and severity thresholds (moderate or severe dementia, 19%-23%) were also frequent. Reasons for ineligibility were similar across phenotypes. Most patients with atypical AD would not meet eligibility criteria for AAT, typically because of MMSE-based exclusion rather than measures of cognitive function. Eligibility rates are broadly similar across atypical phenotypes. These findings highlight the need for phenotype-sensitive staging and patient selection for treatment in atypical AD.
What this study adds
Evidence grade: Low
Among patients with atypical Alzheimer disease phenotypes, 70 to 85 percent would not meet criteria for anti-amyloid treatment, mostly because of bedside cognitive score thresholds. The authors conclude that phenotype-sensitive staging and patient selection are needed for treatment in atypical AD.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Shir, D., Corriveau‐Lecavalier, N., Jones, D. T., Ramanan, V. K., Lachner, C., Knopman, D. S., et al. (2026). Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes. Neurology. https://doi.org/10.1212/wnl.0000000000218347
Vancouver
Shir D, Corriveau‐Lecavalier N, Jones DT, Ramanan VK, Lachner C, Knopman DS, et al. Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes. Neurology. 2026. doi:10.1212/wnl.0000000000218347. PMID: 42555876.
BibTeX
@article{shir2026-42555876,
author = {Shir, Dror and Corriveau‐Lecavalier, Nick and Jones, David Thomas and Ramanan, Vijay K. and Lachner, Christian and Knopman, David S. and Petersen, Ronald Carl and Josephs, Keith A. and others},
title = {{Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes}},
journal = {Neurology},
year = {2026},
doi = {10.1212/wnl.0000000000218347},
pmid = {42555876},
url = {https://doi.org/10.1212/wnl.0000000000218347}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- = 0.036), with lower scores in PCA and lvPPA (median 21 and 21, respectively) compared with CBS-AD (median 27).
- Depending on the eligibility framework applied, 70%-85% of patients would not meet treatment criteria.
- Bedside cognitive thresholds were the primary drivers of ineligibility (50%-67% of exclusions), despite most patients having early symptomatic disease (global CDR 0.5-1; 82%).
- Imaging-based exclusions (22%-27%) and severity thresholds (moderate or severe dementia, 19%-23%) were also frequent.
- Reasons for ineligibility were similar across phenotypes.
Why it matters
Among patients with atypical Alzheimer disease phenotypes, 70 to 85 percent would not meet criteria for anti-amyloid treatment, mostly because of bedside cognitive score thresholds. The authors conclude that phenotype-sensitive staging and patient selection are needed for treatment in atypical AD.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Neill R. Graff‐Radford: h-index 131 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42555876) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000218347
- PubMed: 42555876
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Related studies in Treatments from nearby years
Also in Treatments
203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.